使用双重向策略,研究铁质中介药物诱导肝损伤中的线粒体粘度
Yongqing Zhou1, Yan Wang1, Bing Huang1
1School of Chemistry and Chemical Engineering, University of Jinan, Jinan, 250022, P. R. China.
Advanced science (Weinheim, Baden-Wurttemberg, Germany)
|December 16, 2025
概括
研究人员开发了一种新的近红外光探头 (FTZ-2),用于监测铁质中介药物诱导肝损伤 (DILI) 中的线粒体粘度变化. 这种工具有助于早期诊断和评估针对肝损伤的治疗效果.
科学领域:
- 生物化学 生物化学
- 细胞生物学 细胞生物学
- 医学诊断 医学诊断 医学诊断
背景情况:
- 线粒体粘度是铁质中介药物诱导肝损伤 (DILI) 的关键因素.
- 由于DILI中线粒体功能受损,精确监测粘度变化具有挑战性.
- 在肝损伤中观察到线粒体解蛋白2 (UCP2) 的高表达.
研究的目的:
- 开发一种用于研究铁质中介DILI中的线粒体粘度的新方法.
- 引入线粒体双重准策略,以提高探针定位和选择性.
- 评估一种新的光探针在诊断和评估肝损伤方面的潜力.
主要方法:
- 一个新的近红外光探测器 (FTZ-2) 的合成和特征.
- 开发一种线粒体双重向策略,结合静电反应和探针蛋白对接.
- 应用FTZ-2来监测铁细胞和DILI小鼠模型中的粘度变化.
主要成果:
- "自由贸易区-2"探测器对环境粘度具有很高的选择性.
- FTZ-2表现出有利的细胞毒性和线粒体局部化.
- 减少的光信号与ferrostatin-1,谷氨和N-乙-L-氨酸对肝损伤的缓解作用相关.
- 在ferroptosis和DILI小鼠肝脏中证实了UCP2的高表达.
结论:
- 开发的双重目标策略使得能够有效监测DILI中的线粒体粘度变化.
- FTZ-2 作为一种有价值的工具,用于早期诊断和评估铁死介导的肝损伤.
- 这种方法有助于改善肝损伤的治疗策略.
相关概念视频
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
01:30Drug toxicity: Drug–Drug Interaction
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...